Impact on Clinical. Status and Quality of Life of Switching From Regular Insulin to Insulin Lispro Among Patients Using Insulin Pumps

The Diabetes Educator

Volumn 24, Issue 1, 1998, Pages 95-99

  Campbell, R Keith ^a   Sclar, David A ^a   Robison, Linda M ^a   Stowers, Julie K ^a   Ferguson, Jennifer C ^b   Trippe, Bruce S ^c   Kayne, David M ^d  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c Endocrinology Associates of Montgomcry   (United States)

^d Medical Group of Encino   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN LISPRO;

ADULT; ARTICLE; FEMALE; HUMAN; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INSULIN; MALE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0031612594     PISSN: 01457217     EISSN: None     Source Type: Journal    
DOI: 10.1177/014572179802400113     Document Type: Article

References (16)

1. American Diabetes Association. Diabetes 1996: vital statistics. Alexandria. Va: American Diabetes Association. 1996.
2. Campbell RK, Campbell LK, White JR Insulin lispro: its role in the treatment of diabetes mellitus. Ann Phamiacother. 1996:30: 1263-71.
3. White JR, Campbell RK, Hirsch I. Insulin anatogues. New agents for improving glycemic control. Postgrad Med. 1997;101:58-70.
4. Holleman F., Hoekstra JB Insulin lispro. N Engl J Med. 1997;337:176-83.
5. Jehle PA, Fussgaenger RD, Kunze U., Dolderer M., Warchol W., Koop I. The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab. 1996;81:2319-27.
6. Zinman B., Tildesley H., Chiasson JL, Tsui E., Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997;46: 440-43.
7. Torlone E., Fanclli C., Ramhotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia. 1994:37:713-20.
8. Bohannon N. Benefits of lispro insulin. Control of postprandial glucose levels is within reach. Postgrad Med. 1997;1 10-1:73-80.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14): 977-86.
10. Reichard P., Berglund B., Britz A., Cars I., Nilsson BY, Rusenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intem Med. 1991 : 230:101-8.
11. Marcus AO, Fernandez MP Insulin pump therapy. Acceptable alternative to injection therapy. Postgrad Med. 1996:99:125-43.
12. Unger JR, Fredrickson LP A primer on intensive diabetes management and insutin pump therapy. Primary Care Rep. 1997;3:9-18.
13. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1995;18:8-15.
14. Anderson JH Jr., Brunelle RL, Koivisto VA, et al. Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46: 265-70.
15. Kotsanos JG, Vignati L., Huster W., et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care. 1997 ;20:948-58.
16. Eheling P., Lalli C., Jansson P-A., Bolli GB, Smith U., Koivisto VA Strategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care. 1997;20:1287-89.